Preclinical / Preliminary POC Capabilities ASK KBI Biopharmaceutical development companies seeking product development to support preclinical and/or preliminary proof-of-concept studies are often frustrated by today?s contract services industry. Typical CMOs are either uninterested in these smaller programs or cannot offer viable pricing. There are many research labs, both academic and commercial, that will take on such projects and produce small quantities of product for proof-of-concept (POC) studies, but such work rarely results in scalable processes or reliable product quality. As a result, the client does not receive any meaningful transition to clinical development and cGMP manufacturing in return for their investment. In contrast, KBI is well positioned to help clients create assets from molecules emerging out of discovery.